A strain highly expressing recombinant albumin and its construction method
By co-expressing protein folding and transport-related chaperone genes in Pichia CBS7435, optimizing albumin-encoding genes, and building a combined chaperone expression vector, the problem of low albumin expression was solved, and efficient recombinant albumin production was achieved, reducing the production of high-quality recombinant albumin risk of hypersensitivity reaction.
Patent Information
- Application Number
- CN202410196946.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-22
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-02-22
AI Technical Summary
In the prior art, the expression amount and yield of albumin are low, which is difficult to meet clinical needs. Heterologous proteins may trigger hypersensitivity reactions, and there is a lack of efficient and reliable recombinant albumin production methods.
By constructing highly expressed strains, we can co-express the molecular chaperone protein genes related to protein folding, stress stress response and endoplasmic reticulum transport, optimize the albumin-encoded genes and build a combined molecular chaperone expression vector to improve the correct folding and secretion of recombinant albumin Efficiency, Pichia CBS7435 is used as the expression system.
The expression of recombinant albumin was significantly improved. The expression of recombinant human albumin was 2.10 times that of the initial expression strain, the recombinant canine albumin was 2.26 times, the recombinant cat albumin was 1.95 times, and the recombinant horse albumin was 2.03 times, which increased The secretion and expression efficiency of proteins and reduce the risk of hypersensitivity reactions triggered by heterologous proteins.
Smart Images

Figure CN118222605B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a strain highly expressing recombinant albumin and a construction method thereof, and belongs to the field of medicine. Background Art
[0002] Albumin is synthesized by hepatocytes and is the most abundant protein in plasma. It has multiple physiological functions in the body. It is mainly used clinically for the treatment of shock, cerebral edema caused by blood loss, trauma and burns, as well as critical illnesses such as edema or ascites caused by cirrhosis and kidney disease, and patients with hypoproteinemia. According to statistics, China's annual demand for human albumin is more than 700 tons, of which more than 60% depends on imports. The main source of albumin is blood extraction, but due to limited sources of raw materials, supply exceeds demand, and blood products have the potential risk of carrying pathogens. On the other hand, with the rapid growth of the pet market in recent years, the demand for albumin in animal medicine has also increased. The sources of canine / cat / horse blood albumin are extremely limited, so human albumin is often used in treatment, but heterologous proteins may stimulate the immune system and produce varying degrees of hypersensitivity reactions. With the development of genetic engineering technology, recombinant albumin from various sources has been introduced one after another, but there is currently no recombinant albumin product approved for clinical treatment.
[0003] Research on the expression of albumin has involved a variety of expression systems such as Escherichia coli, yeast, animals and plants, among which the yeast expression system is the most widely used. Yeast is a lower eukaryotic organism. In addition to the characteristics of prokaryotes such as fast cell growth, easy culture, and simple genetic manipulation, it also has the post-processing ability of eukaryotic proteins when expressing proteins, which is very beneficial to the expression of eukaryotic genes. Chinese patent CN202310660983.0 discloses a method for expressing recombinant canine serum albumin, and the protein purity after purification reaches 97%. Chinese patent CN201910975532.X discloses a method for expressing feline serum albumin in Pichia pastoris, and the expression level can reach 2g / L. Chinese patent CN202280003737.1 provides a method for producing canine or feline recombinant albumin using rice suspension cells, wherein the maximum production yield of canine albumin is about 34mg / L, and the maximum production yield of feline albumin is about 58mg / L. Chinese patent CN201911274177.X discloses a recombinant horse serum albumin and its preparation method, which can be used as a stabilizer for rabies vaccine for immunizing horses, with a purity of more than 99%. However, these methods still have defects such as low expression and low yield, and it is necessary to continue to find new methods to construct more high-yield engineered strains.
[0004] Before proteins mature and are secreted into the extracellular space, they undergo a series of post-translational modifications in the secretory pathway. Protein folding, endoplasmic reticulum oxidative stress response, and protein transport in the endoplasmic reticulum and Golgi apparatus often become bottlenecks in the secretion of exogenous proteins. These processes involve the independent or synergistic effects of dozens of key enzyme proteins. Overexpression of molecular chaperones and transcription factors is an effective means to increase the expression level of exogenous proteins. Summary of the invention
[0005] The present invention provides a strain highly expressing recombinant albumin and a construction method thereof. The expression amount of recombinant human albumin of the strain is 2.10 times that of an initial expression strain, the expression amount of recombinant canine albumin is 2.26 times that of the initial expression strain, the expression amount of recombinant cat albumin is 1.95 times that of the initial expression strain, and the expression amount of recombinant horse albumin is 2.03 times that of the initial expression strain.
[0006] To achieve this object, the present invention provides the following technical solutions:
[0007] The first aspect of the present invention provides a method for constructing a strain that highly expresses recombinant albumin, comprising the following steps:
[0008] S1. Construction of albumin initial expression strain;
[0009] S2, constructing a molecular chaperone expression plasmid or a combined molecular chaperone expression vector;
[0010] S3. The molecular chaperone expression plasmid or combined molecular chaperone expression vector constructed in step S2 is transformed into the strain constructed in step S1, and the transformed strain is subjected to positive screening.
[0011] Preferably, step S1 comprises:
[0012] S11, optimizing and artificially synthesizing the albumin encoding gene;
[0013] S12, connecting the optimized sequence to the pPICZαA vector, and the obtained recombinant plasmid was verified to be correct by DNA sequencing;
[0014] S13. The plasmid vector was linearized by Sac I digestion and then electroporated into Pichia pastoris CBS7435 competent cells.
[0015] Preferably, the optimized albumin encoding gene includes:
[0016] Human albumin encoding gene rHSA, the sequence is SEQ ID NO.1;
[0017] Canine albumin encoding gene rCSA, the sequence is SEQ ID NO.2;
[0018] Feline albumin encoding gene rFSA, the sequence is SEQ ID NO.3;
[0019] The horse albumin encoding gene rESA has a sequence of SEQ ID NO.4.
[0020] In the present invention, the sequence of SEQ ID NO.1 is:
[0021]
[0022] In the present invention, the sequence of SEQ ID NO.2 is:
[0023]
[0024] In the present invention, the SEQ ID NO.3 sequence is as follows:
[0025] GAAGCCCATCAATCAGAGATAGCCCATAGATTTAACGACCTTGGTGAAGAGCATTT
[0026] CAGGGGTTTGGTTTTAGTGGCCTTTAGTCAGTATTTGCAGCAATGCCCATTTGAGGATC
[0027] ATGTGAAATTGGTCAACGAGGTGACCGAGTTTGCTAAAGGTTGTGTGGCTGACCAATC
[0028] TGCTGCTAACTGCGAAAAGTCTTTACACGAACTTTTAGGCGACAAATTGTGTACTGTT
[0029] GCTTCCTTGCGTGACAAGTACGGTGAGATGGCTGACTGTTGTGAAAAGAAGGAACCA
[0030] GAAAGAAATGAATGCTTTCTGCAACACAAGGACGACAACCCTGGATTTGGTCAATTAG
[0031] TTACTCCTGAGGCCGACGCTATGTGTACTGCTTTTCATGAGAATGAACAACGATTCCTG
[0032] GGTAAATACTTGTACGAAATTGCTCGAAGGCACCCTTACTTCTATGCTCCTGAGCTGCT
[0033] ATATTACGCTGAAGAATATAAGGGAGTGTTCACGGAATGTTGCGAGGCCGCTGATAAG
[0034] GCTGCATGTTTAACGCCAAAGGTCGACGCCTTGAGAGAAAAGGTCCTGGCTTCTAGTG
[0035] CTAAGGAGAGGCTAAAGTGTGCCAGTTTGCAGAAATTTGGCGAGAGAGCATTTAAGG
[0036] CCTGGTCTGTAGCTAGACTGTCTCAGAAGTTCCCTAAAGCAGAATTTGCTGAGATATCT
[0037] AAACTGGTCACTGATCTTGCTAAGATTCATAAGGAGTGTTGTCATGGCGATTTGTTGGA
[0038] ATGCGCTGACGATAGAGCTGATTTGGCTAAATATATTTGCGAGAACCAAGACTCAATCA
[0039] GTACTAAACTGAAGGAGTGCTGCGGCAAACCAGTTTTGGAAAAGTCCCACTGTATTTC
[0040] AGAAGTGGAGAGAGATGAATTGCCAGCTGATCTACCTCCATTGGCTGTAGATTTCGTG
[0041] GAAGACAAGGAAGTTTGCAAGAACTACCAGGAGGCAAAGGATGTTTTTCTTGGTACA
[0042] TTTTTGTACGAGTATTCAAGAAGGCACCCTGAGTACTCTGTTAGTTTGTTGTTGAGACT
[0043] TGCCAAGGAGTATGAAGCAACGCTGGAAAAATGCTGTGCCACAGATGATCCTCCAGCT
[0044] TGTTATGCTCACGTTTTTGACGAATTCAAGCCATTAGTGGAAGAGCCTCATAATTTGGT
[0045] CAAGACCAATTGCGAGCTATTCGAAAAGTTGGGTGAATACGGTTTTCAGAACGCTCTG
[0046] TTAGTAAGATATACCAAAAAGGTTCCTCAAGTGTCTACTCCTACTTTAGTTGAGGTTTC
[0047] CAGGTCTCTAGGTAAGGTGGGTTCTAAATGTTGTACACATCCAGAAGCAGAGCGTCTT
[0048] AGTTGTGCTGAAGACTACTTATCCGTTGTCTTGAACCGTCTTTGTGTTTTGCATGAGAA
[0049] AACACCCGTCTCCGAGAGAGTGACGAAATGTTGCACTGAGTCATTGGTGAATCGTAGG
[0050] CCCTGCTTCTCTGCACTACAAGTCGACGAAACTTACGTTCCTAAAGAATTCTCAGCAG
[0051] AAACCTTCACTTTTCATGCTGACTTGTGCACACTACCAGAGGCCGAAAAACAGATCAA
[0052] GAAGCAAAGTGCTCTGGTTGAACTACTTAAGCATAAACCAAAGGCAACAGAGGAACA
[0053] ATTGAAAACTGTAATGGGCGACTTTGGATCCTTTGTTGACAAGTGTTGTGCAGCAGAA
[0054] GACAAAGAAGCATGCTTTGCCGAAGAGGGTCCTAAATTGGTTGCCGCCGCACAGGCT
[0055] GCCTTGGCTTAA。
[0056] In the present invention, the sequence of SEQ ID NO.4 is:
[0057]
[0058] Preferably, in step S2, constructing a molecular chaperone expression plasmid comprises:
[0059] S21, amplification of the gene sequences of molecular chaperone proteins PDI, HAC1, GCN4, and SEC1;
[0060] S22, digesting the PCR product of step S21 with Xho I and Not I and ligating it to the vector pPIC6 A. The ligation products were named pPIC6 A-PDI, pPIC6 A-HAC1, pPIC6 A-GCN4, and pPIC6 A-SEC1, respectively;
[0061] S23. The recombinant plasmid obtained in step S22 is verified by DNA sequencing.
[0062] Preferably, in step S2, constructing a combined molecular chaperone expression vector comprises: using the constructed molecular chaperone plasmid as a backbone, and using the 2A peptide and another molecular chaperone to be inserted as insertion fragments to construct them downstream of the sequence of the first molecular chaperone, and obtaining combined molecular chaperone expression vectors which are named pPIC6 A-PDI-HAC1, pPIC6 A-PDI-GCN4, pPIC6A-PDI-SEC1, pPIC6 A-HAC1-GCN4, pPIC6 A-HAC1-SEC1, and pPIC6 A-GCN4-SEC1 respectively.
[0063] Preferably, the amino acid series of the molecular chaperones corresponding to pPIC6 A-PDI, pPIC6 A-HAC1, pPIC6 A-GCN4, and pPIC6 A-SEC1 are: SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.8, and SEQ ID NO.9, respectively; the amino acid series of the combined molecular chaperones corresponding to pPIC6A-PDI-HAC1, pPIC6 A-PDI-GCN4, pPIC6 A-PDI-SEC1, pPIC6 A-HAC1-GCN4, pPIC6 A-HAC1-SEC1, and pPIC6 A-GCN4-SEC1 are: SEQ ID NO.24, SEQID NO.25, SEQ ID NO.26, SEQ ID NO.27, SEQ ID NO.28, and SEQ ID NO.29, respectively.
[0064] In the present invention, the sequence of SEQ ID NO.5 is:
[0065] MKLLSLALLVSLVSADTFYTPKDDVIQLNAYNFKDVVFNSNYSSVVEFYAPWCGHCQNLKNPFKKAAAVSKDYLQVAAIDCDAAENKKLCSDYRIQGFPTIMVFRPPKFDPTSSTNRRSGAHANEVYSGARDTKSIVEFGVSRIKNYVKRVSPNNINQTLGNSEKTQLLLVTDKAKPSALIKSIALDFLNDIESFYYPFNDKTKKALTTRLEEYQQSFSGESITSPSILVLHENEIHIFDGKLDKLSISKFLAEFSTPLEGPLSKRGKFLEHIRRGIKPGRKAKKGKKGKQTKNHDEL。
[0066] In the present invention, the sequence of SEQ ID NO.7 is:
[0067] MPVDSSHKTASPLPPRKRAKTEEEKEQRRVERILRNRRAAHASREKKRRHVEFLENHVVDLESALQESAKATNKLKEIQDIIVSRLEALGGTVSDLDLTVPEVDFPKSSDLEPMSDLSTSSKSEKASTSTRRSLTEDLDEDDVAEYDDEEEDEELPRKMKVLNDKNKSTSIKQEKLNELPSPLSSDFSDVDEEKSTLTHLKLQQQQQQPVDNYVSTPLSLPEDSVDFINPGNLKIESDENFLLSSNTLQIKHENDTDYITTAPSGSINDFFNSYDISESNRLHHPAVMTDSSLHITAGSIGFFSLIGGGESSVAGRRSSVGTYQLTCIAIR。
[0068] In the present invention, the sequence of SEQ ID NO.8 is:
[0069] MSASTYSFDQAMDFDIVQSVTSTQDHIPMVLGESVLRSFVGNDANKAPAIKQEYEALPLNAQIVNPELTPSVGTISPLEIHTSVLDSVLSTDFTDADNSPMFESPESEDPNNWVSLFADETTLATTPAVSRAPAASASPVVPSLKTTSGDEQQLTVKQFVEYPSAKDKLSPKSVEKKISFKKDHLGVVGYTRRQRSSPLAPIVVKDDDPVSMKRARNTEAARRSRAKKMKRMSQLEDKVEELLICKSELEAEVERLKSLVKHQ.
[0070] In the present invention, SEQ ID NO.9 sequence is:
[0071] MASDLINLQRDYLLKLIGSVETSNGLKCLVLDANSERLVNSLIDSNTLLRYVTTVERIDKKRKIRLSMEGVYLIGPTKFSVNCLLADFQINPTRYKKAHLLFLSPLARELTNLIMGNKQLEANTITRRTVDFTLLPLESHVFLSDAPDSLPTLYNENCLDLIRYQASRAVQTLMNLCIITGEYPLVRYYSPQNPINKSSVLPRMIAQEFQSTLDDYCRIKQDFPGDNPRPRSIFIITDRTMDLLAPLMHDFTYEAMCFDLLEFAENVDGDYPNTYRYSVENENGELLDREASLKPPIDDYWEELRNMHILDASNQLDVKLNKLITNNPMMVDRDKASGTRDFLFIVAHLHGFDEERRKIMLHKKLTEELLVINNERHLAECADFEQNCAAFGVSYDGEKIKDMASFLLSWISLDYFTTSDKIRLILIYAIYRGGLIRADVSKLVKFAGLASAEEHVMTLFENFSLLGFQLLKAHPKDKSFKKQFWHKIDSNAVLNTSRYKPAIQAIVELASKGILDEASFPYIKDKPLEVSETNPDSATSLKNPRYRAAWSRKGSSYSPPKQRIVVYSAGGITYSEMKAGYDAGCLLNKDVFIGSDEVITPRMFVNNVIDLTSDRASLSLFYDRRRAAGESAPKVLFEQESHHRPSIGGPVDSSASLASTTSQSHEPPTNDKEKHRKRDKLKKFWK。
[0072] In the present invention, the SEQ ID NO.24 sequence is as follows:
[0073] MKLLSLALLVSLVSADTFYTPKDDVIQLNAYNFKDVVFNSNYSSVVEFYAPWCGHCQNLKNPFKKAAAVSKDYLQVAAIDCDAAENKKLCSDYRIQGFPTIMVFRPPKFDPTSSTNRRSGAHANEVYSGARDTKSIVEFGVSRIKNYVKRVSPNNINQTLGNSEKTQLLLVTDKAKPSALIKSIALDFLNDIESFYYPFNDKTKKALTTRLEEYQQSFSGESITSPSILVLHENEIHIFDGKLDKLSISKFLAEFSTPLEGPLSKRGKFLEHIRRGIKPGRKAKKGKKGKQTKNHDELGSGATNFSLLKQAGDVEENPGPMPVDSSHKTASPLPPRKRAKTEEEKEQRRVERILRNRRAAHASREKKRRHVEFLENHVVDLESALQESAKATNKLKEIQDIIVSRLEALGGTVSDLDLTVPEVDFPKSSDLEPMSDLSTSSKSEKASTSTRRSLTEDLDEDDVAEYDDEEEDEELPRKMKVLNDKNKSTSIKQEKLNELPSPLSSDFSDVDEEKSTLTHLKLQQQQQQPVDNYVSTPLSLPEDSVDFINPGNLKIESDENFLLSSNTLQIKHENDTDYITTAPSGSINDFFNSYDISESNRLHHPAVMTDSSLHITAGSIGFFSLIGGGESSVAGRRSSVGTYQLTCIAIR。
[0074] In the present invention, the SEQ ID NO.25 sequence is as follows:
[0075] 。
[0076] In the present invention, SEQ ID NO.26 sequence is:
[0077] MKLLSLALLVSLVSADTFYTPKDDVIQLNAYNFKDVVFNSNYSSVVEFYAPWCGHCQNL
[0078] KNPFKKAAAVSKDYLQVAAIDCDAAENKKLCSDYRIQGFPTIMVFRPPKFDPTSSTNRRS
[0079] GAHANEVYSGARDTKSIVEFGVSRIKNYVKRVSPNNINQTLGNSEKTQLLLVTDKAKPSA
[0080] LIKSIALDFLNDIIESFYYPFNDKTKKALTTRLEEYQQSFSGESITSPSILVLHENEIHIFDGKL
[0081] DKLSISKFLAEFSTPLEGPLSKRRGKFLEHIRRGIKPGRKAKKKGKKKGQTKNHDELGSGATN
[0082] FSLLKQAGDVEENPGPMASDLINLQRDYLLKLIGSVETSNGLKCLVLDANSERLVNSLIDS
[0083] NTLLRYVTTVERIDKKRKIRLSMEGVYLIGPTKFSVNCLLADFQINPTRYKKAHLLFLSPL
[0084] ARELTNLIMGNKQLEANTITRRTVDFTLLPLESHVFLSDAPDSLPTLYNENCLDLIRYQASR
[0085] AVQTLMNLCIITGEYPLVRYYSPQNPINKSSVLPRMIAQEFQSTLDDYCRIKQDFPGDNPRP
[0086] RSIFIITDRTMDLLAPLMHDFTYEAMCFDLEFAENVDGDYPNTYRYSVENENGELLDRE
[0087] ASLKPPIDDYWEELRNMHILDASNQLDVKLNKLITNNPMMVDRDKASGTRDFLFIVAHL
[0088] HGFDEERRKIMLHKKLTEELLWINNERHLAECADFEQNCAAFGVSYDGEKIKDMASFLLS
[0089] WISLDYFTTSDKIRLILIYAIYRGGLIRADVSKLVKFAGLASAEEHVMTLFENFSLLGFQLL
[0090] KAHPKDKSFKKQFWHKIDSNAVLNTSRYKPAIQAIVELASKGILDEASFPYIKDKPLEVSE
[0091] TNPDSATSLKNPRYRAAWSRKGSSYSPPKQRIVVYSAGGITYSEMKAGYDAGCLLNKDV
[0092] FIGSDEVITPRMFVNNVIDLTSDRASLSLFYDRRRAAGESAKPVLFEQESHHRPSIGGPVDSSASLASTTSQSHEPPTNDKEKHRKRDKLKKFWK。
[0093] In the present invention, SEQ ID NO.27 is sequenced as:
[0094] 。
[0095] In the present invention, SEQ ID NO.28 is sequenced as:
[0096]
[0097] In the present invention, the sequence of SEQ ID NO.29 is:
[0098] 。
[0099] Preferably, the P2A nucleotide sequence used is shown as SEQ ID NO.11.
[0100] In the present invention, the sequence of SEQ ID NO.11 is:
[0101] GGTAGTGGCGCCACCAACTTCAGCCTGCTGAAGCAGGCCGGCGACGTGGAGGAG AACCCTGGACCT.
[0102] The second aspect of the present invention provides a strain that highly expresses recombinant albumin, and the strain is constructed by the method described in the present invention.
[0103] Preferably, the method comprises the following steps:
[0104] S1. Construction of albumin initial expression strain;
[0105] S2, constructing a molecular chaperone expression plasmid or a combined molecular chaperone expression vector;
[0106] S3. The molecular chaperone expression plasmid or combined molecular chaperone expression vector constructed in step S2 is transformed into the strain constructed in step S1, and the transformed strain is subjected to positive screening.
[0107] Preferably, step S1 comprises:
[0108] S11, optimizing and artificially synthesizing the albumin encoding gene;
[0109] S12, connecting the optimized sequence to the pPICZαA vector, and the obtained recombinant plasmid was verified to be correct by DNA sequencing;
[0110] S13. The plasmid vector was linearized by Sac I digestion and then electroporated into Pichia pastoris CBS7435 competent cells.
[0111] Preferably, the optimized albumin encoding gene includes:
[0112] Human albumin encoding gene rHSA, the sequence is SEQ ID NO.1;
[0113] Canine albumin encoding gene rCSA, the sequence is SEQ ID NO.2;
[0114] Feline albumin encoding gene rFSA, the sequence is SEQ ID NO.3;
[0115] The horse albumin encoding gene rESA has a sequence of SEQ ID NO.4.
[0116] Preferably, in step S2, constructing a molecular chaperone expression plasmid comprises:
[0117] S21, amplify the gene sequences of molecular chaperone proteins PDI, HAC1, GCN4, and SEC1;
[0118] S22, digesting the PCR product of step S21 with Xho I and Not I and ligating it to the vector pPIC6 A. The ligation products were named pPIC6 A-PDI, pPIC6 A-HAC1, pPIC6 A-GCN4, and pPIC6 A-SEC1, respectively;
[0119] S23. The recombinant plasmid obtained in step S22 is verified by DNA sequencing.
[0120] Preferably, in step S2, constructing a combined molecular chaperone expression vector comprises: using the constructed molecular chaperone plasmid as a backbone, and using the 2A peptide and another molecular chaperone to be inserted as insertion fragments to construct them downstream of the sequence of the first molecular chaperone, and obtaining combined molecular chaperone expression vectors which are named pPIC6 A-PDI-HAC1, pPIC6 A-PDI-GCN4, pPIC6A-PDI-SEC1, pPIC6 A-HAC1-GCN4, pPIC6 A-HAC1-SEC1, and pPIC6 A-GCN4-SEC1 respectively.
[0121] Preferably, the amino acid series of the molecular chaperones corresponding to pPIC6 A-PDI, pPIC6 A-HAC1, pPIC6 A-GCN4 and pPIC6 A-SEC1 are: SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.8 and SEQ ID NO.9 respectively.
[0122] Preferably, the amino acid series of the combined molecular chaperones corresponding to pPIC6 A-PDI-HAC1, pPIC6 A-PDI-GCN4, pPIC6 A-PDI-SEC1, pPIC6 A-HAC1-GCN4, pPIC6 A-HAC1-SEC1, and pPIC6 A-GCN4-SEC1 are: SEQ ID NO.24, SEQ ID NO.25, SEQ ID NO.26, SEQ ID NO.27, SEQ ID NO.28, and SEQID NO.29, respectively.
[0123] Preferably, the P2A nucleotide sequence used is shown as SEQ ID NO.11.
[0124] Preferably, the strain is Pichia pastoris CBS7435 strain.
[0125] Compared with the prior art, the beneficial effects and significant improvements of the technical solution of the present invention are:
[0126] 1. The method of the present invention promotes the correct folding and efficient secretion of the target protein by co-expressing molecular chaperone protein genes related to protein folding, stress response, and protein transport in the endoplasmic reticulum and Golgi apparatus;
[0127] 2. The four molecular chaperone proteins and six molecular chaperone combinations screened by the present invention can effectively improve the secretion expression of recombinant human, canine, cat or horse albumin;
[0128] 3. The present invention verified that the combined molecular chaperone PDI-SEC1 showed the best enhancement effect, among which the expression level of recombinant human albumin was 2.10 times that of the initial expression strain, the expression level of recombinant canine albumin was 2.26 times that of the initial expression strain, the expression level of recombinant feline albumin was 1.95 times that of the initial expression strain, and the expression level of recombinant horse albumin was 2.03 times that of the initial expression strain. BRIEF DESCRIPTION OF THE DRAWINGS
[0129] In order to more clearly illustrate the technical solution of the present invention, the drawings used in the embodiments of the present invention are briefly introduced below.
[0130] Figure 1 is a schematic diagram of the structure of pPICZαA-rHSA in Example 1;
[0131] Figure 2 is a schematic diagram of the structure of pPICZαA-rCSA in Example 1;
[0132] Figure 3 is a schematic diagram of the structure of pPICZαA-rFSA in Example 1;
[0133] Figure 4 Schematic diagram of the structure of pPICZαA-rESA in Example 1.
[0134] Figure 5 This is the SDS-PAGE electrophoresis diagram of the purified recombinant canine albumin in Example 7;
[0135] Figure 6 The changes in plasma colloid osmotic pressure of rats with cirrhosis and ascites after administration to different treatment groups in Example 8 for 10 days;
[0136] Figure 7 The changes in albumin concentrations in rats with cirrhosis and ascites after administration to different treatment groups in Example 8 for 10 days. DETAILED DESCRIPTION
[0137] The present invention is further described below in conjunction with specific examples. The examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content of the present invention, those skilled in the art can make various changes and modifications to the present invention, and these equivalent forms also fall within the scope limited by the appended claims of the application.
[0138] In order to more fully understand the present invention, the professional terms in the present invention are explained below.
[0139] The "recombinant plasmid" of the present invention has a target gene and a plasmid, and then the two are connected by an enzyme to form a recombinant plasmid. Plasmids have the advantages of stability, reliability and ease of operation. If you want to clone a small DNA fragment (<10kb) with a simple structure, plasmids are better than any other vectors. In principle, cloning on a plasmid vector is very simple. First, use a restriction endonuclease to cut the plasmid DNA and the target DNA fragment, then connect the two in vitro, and then use the obtained recombinant plasmid to transform bacteria.
[0140] The "strain" of the present invention refers to any pure population and its offspring that is reproduced from an independently isolated single cell (or a single virus particle). Therefore, each pure culture of a microorganism from different sources can be called a strain of the species. According to the definition of strain, the strain is actually a sign that a certain microorganism has reached "genetic purity". Once the strain mutates, it should be labeled with a new strain name. When carrying out strain preservation, screening or scientific research, when conducting academic exchanges or publishing papers, and when using strains for production, the species and strain name must be indicated at the same time.
[0141] The "peptide" of the present invention is a compound in which two or more amino acids are connected by peptide bonds, which plays an important physiological role in the human body and exerts physiological functions. Active polypeptides are called active peptides, also known as bioactive peptides or bioactive polypeptides.
[0142] The "molecular chaperones" of the present invention are proteins that have no sequence correlation but have common functions. They help other polypeptide-containing structures to complete the correct assembly in the cell, and are separated from them after assembly. They do not constitute components for these protein structures to perform functions. In other words, a class of proteins in the cytoplasm that can recognize and bind to incompletely folded or assembled proteins, help these polypeptides to fold correctly, transport or prevent them from aggregation, and do not participate in the formation of the final product itself.
[0143] Example 1 Construction of albumin initial expression strain
[0144] 1.1. The human, dog, cat and horse albumin coding genes were optimized and artificially synthesized according to the codon preference of the Pichia pastoris expression system. The sequences of the human albumin coding gene rHSA, the dog albumin coding gene rCSA, the cat albumin coding gene rFSA and the horse albumin coding gene rESA are shown in Table 1 below;
[0145] 1.2. The optimized sequence was connected to the pPICZαA vector (with restriction sites PmII and XbaI). The obtained recombinant plasmids were verified to be correct by DNA sequencing and named pPICZαA-rHSA, pPICZαA-rCSA, pPICZαA-rFSA and pPICZαA-rESA, respectively. The plasmid structures are as follows: Figure 1 , Figure 2 , Figure 3 , Figure 4 As shown;
[0146] 1.3. Linearize the plasmid vector by Sac I digestion and then electro-transform it into CBS7435 competent cells;
[0147] 1.4. Spread the transformed strains on YPD resistance plates (containing zeocin 200 μg / mL), pick the positive single clones, and obtain the recombinant albumin initial expression strains, which were named CBS7435-rHSA, CBS7435-rCSA, CBS7435-rFSA and CBS7435-rESA respectively.
[0148] Table 1 Albumin coding gene sequence list
[0149]
[0150]
[0151]
[0152]
[0153]
[0154] Example 2 Construction of chaperone expression plasmid
[0155] 2.1. Based on the gene sequences of molecular chaperone proteins PDI, Kar2p, HAC1, GCN4, SEC1, and SLY1 in the NCBI database, the following primers were designed for gene amplification (restriction sites are underlined). The sequences of molecular chaperone amplification primers are shown in Table 2.
[0156] Table 2 Molecular chaperone amplification primer sequence list
[0157]
[0158]
[0159] 2.2. Using the genome of Pichia pastoris CBS7435 as a template, the gene sequences of PDI, Kar2p, HAC1, SEC1 and SLY1 were amplified by PCR reaction; using the genome of Pichia pastoris GS115 as a template, the gene sequence of GCN4 was amplified by PCR reaction. The PCR products were digested with Xho I and Not I and then connected with the vector pPIC6 A. The obtained recombinant plasmids were verified to be correct by DNA sequencing and named pPIC6 A-PDI, pPIC6 A-Kar2p, pPIC6 A-HAC1, pPIC6 A-GCN4, pPIC6 A-SEC1, pPIC6 A-SLY1, and the corresponding amino acid sequences of the molecular chaperones are shown in Table 3.
[0160] Table 3 Molecular chaperone sequence list
[0161]
[0162]
[0163]
[0164] Example 3 Construction of a strain for co-expression of recombinant canine albumin and molecular chaperones and shake flask induced expression
[0165] Experimental methods
[0166] 3.1. The recombinant canine albumin expression strain constructed in Example 1 was used as the original strain. The recombinant plasmid constructed in Example 2 was linearized by SacⅠ and then electrotransformed into the CBS7435-rCSA strain. The transformed strain was spread on a YPD resistance plate (containing 200 μg / mL of Blasticidin) for positive screening. The obtained positive transformants were named CBS7435-rCSA-PDI, CBS7435-rCSA-Kar2p, CBS7435-rCSA-HAC1, CBS7435-rCSA-GCN4, CBS7435-rCSA-SEC1, and CBS7435-rCSA-SLY1.
[0167] 3.2. Pick the positive single colonies of the above strains respectively, inoculate them into 5 mL YPD liquid medium for overnight culture, take 1 mL and inoculate it into 100 mL BMGY medium, culture at 28°C and 220 rpm until OD600 is about 6, collect the bacteria by centrifugation, transfer to 40 mL BMMY medium, and induce culture at 25°C and 220 rpm, add 0.4% methanol every 24 h, and induce for a total of 72 h.
[0168] 3.3. After induction, the supernatant was collected for SDS-PAGE analysis.
[0169] Experimental Results
[0170] The results are shown in Table 4. Compared with the initial expression strain of recombinant canine albumin (CBS7435-rCSA), co-expression of molecular chaperones PDI, HAC1, GCN4 and SEC1 significantly increased the expression level of recombinant canine albumin, while the remaining two groups had no improvement effect.
[0171] Table 4 Expression of recombinant canine albumin in chaperone co-expression strains
[0172] strains Expression ratio CBS7435-rCSA 100% CBS7435-rCSA-PDI 205% CBS7435-rCSA-Kar2p 94% CBS7435-rCSA-HAC1 180% CBS7435-rCSA-GCN4 123% CBS7435-rCSA-SEC1 152% CBS7435-rCSA-SLY1 79%
[0173] Example 4 Construction of Combination Molecular Chaperone Expression Vector
[0174] The molecular chaperones PDI, HAC1, GCN4, and SEC1 that have improved protein expression in Example 3 are combined in pairs and connected by 2A peptide. The single molecular chaperone plasmid constructed in Example 2 is used as the skeleton, and the 2A peptide and the second molecular chaperone to be inserted are used as the insertion fragment to construct the sequence downstream of the first molecular chaperone. The P2A nucleotide sequence used is SEQ ID NO.11 (GGTAGTGGCGCCACCAACTTCAGCCTGCTGAAGCAGGCCGGCGACG TGGAGGAGAACCCTGGACCT), and the combined molecular chaperone expression vector is obtained. The DNA sequence is verified to be correct and named pPIC6 A-PDI-HAC1, pPIC6A-PDI-GCN4, pPIC6 A-PDI-SEC1, pPIC6A-HAC1-GCN4, pPIC6 A-HAC1-SEC1, and pPIC6 A-GCN4-SEC1. The corresponding sequences of the combined molecular chaperones are shown in Table 5.
[0175] Table 5 Combination molecular chaperone sequence list
[0176]
[0177]
[0178]
[0179]
[0180] Example 5 Construction of co-expression strain of recombinant canine albumin and combined molecular chaperone and shake flask induced expression experimental method
[0181] 5.1. The combined molecular chaperone expression vector constructed in Example 4 was linearized by SacⅠ and then electroporated into the CBS7435-rCSA strain. The transformed strain was spread on YPD resistance plates (containing 200 μg / mL of Blasticidin) for positive screening. The obtained positive transformants were named CBS7435-rCSA-PDI-HAC1, CBS7435-rCSA-PDI-GCN4, CBS7435-rCSA-PDI-SEC1, CBS7435-rCSA-HAC1-GCN4, CBS7435-rCSA-HAC1-SEC1, and CBS7435-rCSA-GCN4-SEC1.
[0182] 5.2. Pick the positive single colonies of the above strains respectively, inoculate them into 5 mL YPD liquid medium for overnight culture, take 1 mL and inoculate it into 100 mL BMGY medium, culture at 28°C and 220 rpm until OD600 is about 6, collect the bacteria by centrifugation, transfer to 40 mL BMMY medium, and induce culture at 25°C and 220 rpm, add 0.4% methanol every 24 hours, and induce for a total of 72 hours.
[0183] 5.3. After induction, collect the supernatant for SDS-PAGE detection.
[0184] Experimental Results
[0185] The results are shown in Table 6. Compared with the initial expression strain of recombinant canine albumin (CBS7435-rCSA), each combined molecular chaperone co-expression strain increased the expression level of recombinant canine albumin, among which CBS7435-rCSA-PDI-SEC1 had the best effect, and the expression level of recombinant canine albumin was 2.26 times that of the initial strain.
[0186] Table 6 Expression of recombinant canine albumin in the combined molecular chaperone co-expression strains
[0187] strains Expression ratio CBS7435-rCSA 100% CBS7435-rCSA-PDI-HAC1 211% CBS7435-rCSA-PDI-GCN4 165% CBS7435-rCSA-PDI-SEC1 226% CBS7435-rCSA-HAC1-GCN4 144% CBS7435-rCSA-HAC1-SEC1 127% CBS7435-rCSA-GCN4-SEC1 130%
[0188] Example 6 Fermentation culture of recombinant canine albumin
[0189] Taking strain CBS7435-rCSA-PDI-SEC1 as an example, a 50L fermenter was used for fermentation culture.
[0190] 6.1. Culture medium preparation
[0191] PTM1: 3 g copper sulfate pentahydrate, 0.044 g potassium iodide, 1.5 g manganese sulfate monohydrate, 0.1 g sodium molybdate dihydrate, 0.01 g boric acid, 0.25 g cobalt chloride, 10 g zinc chloride, 32.5 g ferrous sulfate heptahydrate, 0.1 g biotin, 2.5 mL sulfuric acid, dilute to 500 mL, filter and sterilize.
[0192] BSM: 534 mL of 85% phosphoric acid, 18.6 g of calcium sulfate dihydrate, 364 g of potassium sulfate, 298 g of magnesium sulfate dihydrate, 82.6 g of potassium hydroxide, 800 g of glycerol, make up to 20 L, sterilize and cool, add 80 mL of sterilized PTM1 solution, adjust the pH to 5.0 with ammonia water, and put into the fermentation tank.
[0193] Glycerol phase feed: 4200 g of glycerol, 2800 g of purified water, 0.2 mL / L of defoamer, 80 mL of PTM1, mixed and placed in a 10 L storage bottle for sterilization.
[0194] Feed during the induction period: 20 L of methanol, filtered and sterilized; 0.2 mL / L of defoaming agent, sterilized and dissolved in the sterilized methanol.
[0195] 6.2 Fermentation culture
[0196] Take the preserved strain for plate streaking, pick a single colony and inoculate it in 500mL YPD liquid medium, culture at 28℃ and 220rpm, wait for the shake flask seed OD600 to reach 10, connect to the fermenter, keep the temperature at 28±1℃, pH 5.0±0.2, speed 300-1000rpm, dissolved oxygen 30%, tank pressure 0.05Mpa, ventilation volume 20L / min. When the dissolved oxygen rebounds, enter the glycerol stage, start to flow glycerol, and the parameter requirements remain unchanged. After 10 hours of glycerol feeding, enter the mixed feeding stage, glycerol feeding and methanol feeding are fed at the same time, pH is adjusted to 6.0, and the temperature is reduced to 25℃. After 2 hours of flow, enter the methanol feeding stage, flow methanol feeding, and monitor each fermentation parameter in real time. Samples are taken at intervals during the fermentation, and OD600 and wet weight are measured. When OD600 and wet weight no longer increase, it is the end point of the collection and the tank is released. The fermentation product is centrifuged at 8000rpm for 20 minutes, and the supernatant is collected for subsequent purification.
[0197] Example 7 Purification of recombinant canine albumin
[0198] Experimental methods
[0199] The fermentation supernatant was centrifuged at 12000rpm for 15min, the precipitate was discarded, the supernatant was collected, and the mixture was repeated twice. The mixture was filtered through a 0.22μm filter membrane to obtain a recombinant canine albumin stock solution. First, hydrophobic chromatography was performed using Phenyl Sepharose 6FastFlow (High Sub) as the filler. Five column volumes were balanced with an equilibrium buffer of 50mM H3PO4+150mM NaCl, pH 6.8±0.1, and the sample was loaded and the flow-through was collected. The flow-through was ultrafiltered using a 30K ultrafiltration membrane package, and ultrafiltration buffer 5mM H3PO4 was added at a ratio of 1:1 for desalting. Then anion exchange chromatography was performed, using Monomix HC60-DEAE Excel as filler, equilibrated with 100 mM H3PO4, pH 7.3 ± 0.1 equilibrium buffer for 5 column volumes, sample loading, elution with 50 mM H3PO4, pH 6.8 ± 0.1 elution buffer, collection of eluted fractions and 30K ultrafiltration concentration, the concentrate was sterilized by filtration through a 0.22 μm filter membrane and stored at 4°C. Purity test of purified recombinant canine albumin was performed.
[0200] Experimental Results
[0201] SDS-PAGE results are as follows Figure 5 As shown, the results showed that the main band of the target protein was clear, no obvious mixed bands were found, and the protein purity was about 99.3%; the bacterial endotoxin test result was less than 0.5EU / mg.
[0202] Example 8 Administration experiment of recombinant canine albumin to rats with liver cirrhosis and ascites model
[0203] Experimental methods
[0204] 36 rats with liver cirrhosis and ascites were selected and randomly divided into 3 groups, namely, the negative control group: sodium chloride injection (purchased from Changchun Tiancheng Pharmaceutical Co., Ltd.); the positive control group: canine blood albumin injection (purchased from Beijing Century Yuanheng Animal Epidemic Prevention Technology Co., Ltd.); the experimental group: the purified recombinant canine albumin in Example 7 was diluted to 10% with sodium chloride injection. The dosage of each group was 2mL / kg, and the administration method was intra-caudal vein push injection, and the tail vein was embedded with a retaining needle. The administration was once a day for 10 consecutive days, and the interval between two administrations was 24h. The administration speed was controlled to ensure that each administration was a small amount and multiple times and the infusion was completed within 2h. Blood was collected from the orbital vein 18h after the last administration to determine the plasma colloid osmotic pressure and albumin concentration.
[0205] Experimental Results
[0206] The results are shown in Tables 7 and 8. The changes before and after administration are as follows: Figure 6 and Figure 7After 10 days of administration, the plasma colloidal osmotic pressure of rats in the positive control group and the experimental group increased, and the albumin concentration returned to normal levels, indicating that the recombinant canine albumin in the present invention has the same therapeutic effect as natural canine serum albumin in treating liver cirrhosis ascites.
[0207] Table 7 Plasma colloid osmotic pressure before and after administration in different treatment groups
[0208] drug Before administration (mmHg) 10 days after administration (mmHg) Sodium Chloride Injection 14.38±0.35 14.71±0.47 Canine Blood Albumin Injection 14.42±0.46 23.82±1.12 Recombinant Canine Albumin 14.40±0.44 23.78±0.53
[0209] Table 9 Plasma albumin concentrations before and after administration in different treatment groups
[0210] drug Before administration (g / L) 10 days after administration (g / L) Sodium Chloride Injection 22.95±1.62 21.84±1.34 Canine Blood Albumin Injection 22.54±1.95 34.95±1.85 Recombinant Canine Albumin 23.04±2.34 35.52±1.78
[0211] Example 9 Construction of co-expression strain of recombinant human albumin and molecular chaperone / combination molecular chaperone and protein expression
[0212] Experimental methods
[0213] The recombinant human albumin expression strain constructed in Example 1 was used as the original strain, and the recombinant plasmids pPIC6A-PDI, pPIC6 A-HAC1, pPIC6 A-GCN4, pPIC6 A-SEC1, pPIC6 A-PDI-HAC1, pPIC6 A-PDI-GCN4, pPIC6 A-PDI-SEC1, pPIC6 A-HAC1-GCN4, pPIC6 A-HAC1-SEC1, and pPIC6 A-GCN4-SEC1 were linearized by SacⅠ and then electroporated into the CBS7435-rHSA strain. The transformed strains were spread on YPD resistance plates (containing Blasticidin 200 μg / mL) was used for positive screening, and the obtained positive transformants were named CBS7435-rHSA-PDI, CBS7435-rHSA-HAC1, CBS7435-rHSA-GCN4, CBS7435-rHSA-SEC1, CBS7435-rHSA-PDI-HAC1, CBS7435-rHSA-PDI-GCN4, CBS7435-rHSA-PDI-SEC1, CBS7435-rHSA-HAC1-GCN4, CBS7435-rHSA-HAC1-SEC1, and CBS7435-rHSA-GCN4-SEC1. Pick the positive single colonies of the above strains, inoculate them into 5mL YPD liquid medium for overnight culture, take 1mL and inoculate them into 100mL BMGY medium, culture them at 28℃ and 220rpm until OD600 is about 6, collect the bacteria by centrifugation, transfer to 40mL BMMY medium, and induce them at 25℃ and 220rpm. Add 0.4% methanol every 24h for a total of 72h. After the induction, collect the supernatant for SDS-PAGE detection.
[0214] Experimental Results
[0215] The results are shown in Table 9. Compared with the initial expression strain of recombinant human albumin (CBS7435-rHSA), each molecular chaperone expression strain increased the secretion expression of recombinant human albumin, and the expression level of the co-expressed molecular chaperone PDI-SEC1 protein was 2.10 times the original.
[0216] Table 9 Expression of recombinant human albumin in chaperone co-expression strains
[0217] strains Expression ratio CBS7435-rHSA 100% CBS7435-rHSA-PDI 198% CBS7435-rHSA-HAC1 183% CBS7435-rHSA-GCN4 145% CBS7435-rHSA-SEC1 164% CBS7435-rHSA-PDI-HAC1 182% CBS7435-rHSA-PDI-GCN4 171% CBS7435-rHSA-PDI-SEC1 210% CBS7435-rHSA-HAC1-GCN4 145% CBS7435-rHSA-HAC1-SEC1 129% CBS7435-rHSA-GCN4-SEC1 137%
[0218] Example 10 Construction of co-expression strain of recombinant feline albumin and molecular chaperone / combination molecular chaperone and protein expression experimental method
[0219] The recombinant feline albumin expression strain constructed in Example 1 was used as the original strain, and the recombinant plasmids pPIC6A-PDI, pPIC6 A-HAC1, pPIC6 A-GCN4, pPIC6 A-SEC1, pPIC6 A-PDI-HAC1, pPIC6 A-PDI-GCN4, pPIC6 A-PDI-SEC1, pPIC6 A-HAC1-GCN4, pPIC6 A-HAC1-SEC1, and pPIC6 A-GCN4-SEC1 were linearized by SacⅠ and then electrotransformed into the CBS7435-rFSA strain. The transformed strains were spread on YPD resistance plates (containing Blasticidin 200 μg / mL) was used for positive screening, and the positive transformants obtained were named CBS7435-rFSA-PDI, CBS7435-rFSA-HAC1, CBS7435-rFSA-GCN4, CBS7435-rFSA-SEC1, CBS7435-rFSA-PDI-HAC1, CBS7435-rFSA-PDI-GCN4, CBS7435-rFSA-PDI-SEC1, CBS7435-rFSA-HAC1-GCN4, CBS7435-rFSA-HAC1-SEC1, and CBS7435-rFSA-GCN4-SEC1. Pick the positive single colonies of the above strains, inoculate them into 5mL YPD liquid medium for overnight culture, take 1mL and inoculate them into 100mL BMGY medium, culture them at 28℃ and 220rpm until OD600 is about 6, collect the bacteria by centrifugation, transfer to 40mL BMMY medium, and induce them at 25℃ and 220rpm. Add 0.4% methanol every 24h for a total of 72h. After the induction, collect the supernatant for SDS-PAGE detection.
[0220] Experimental Results
[0221] The results are shown in Table 10. Compared with the initial expression strain of recombinant feline albumin (CBS7435-rFSA), each chaperone expression strain increased the secretion expression of recombinant feline albumin, among which the co-expression of molecular chaperone PDI and combined molecular chaperone PDI-SEC1 had better effects, with expression levels of 1.91 times and 1.95 times the original, respectively.
[0222] Table 10 Expression of recombinant feline albumin in chaperone co-expression strains
[0223] strains Expression ratio CBS7435-rFSA 100% CBS7435-rFSA-PDI 191% CBS7435-rFSA-HAC1 172% CBS7435-rFSA-GCN4 185% CBS7435-rFSA-SEC1 154% CBS7435-rFSA-PDI-HAC1 140% CBS7435-rFSA-PDI-GCN4 166% CBS7435-rFSA-PDI-SEC1 195% CBS7435-rFSA-HAC1-GCN4 138% CBS7435-rFSA-HAC1-SEC1 136% CBS7435-rFSA-GCN4-SEC1 115%
[0224] Example 11 Construction of a co-expression strain of recombinant horse albumin and molecular chaperones / combination molecular chaperones and protein expression experimental methods
[0225] The recombinant horse albumin expression strain constructed in Example 1 was used as the original strain, and the recombinant plasmids pPIC6A-PDI, pPIC6 A-HAC1, pPIC6 A-GCN4, pPIC6 A-SEC1, pPIC6 A-PDI-HAC1, pPIC6 A-PDI-GCN4, pPIC6 A-PDI-SEC1, pPIC6 A-HAC1-GCN4, pPIC6 A-HAC1-SEC1, and pPIC6 A-GCN4-SEC1 were linearized by SacⅠ and then electroporated into the CBS7435-rESA strain. The transformed strains were spread on YPD resistance plates (containing Blasticidin 200 μg / mL) was used for positive screening, and the positive transformants obtained were named CBS7435-rESA-PDI, CBS7435-rESA-HAC1, CBS7435-rESA-GCN4, CBS7435-rESA-SEC1, CBS7435-rESA-PDI-HAC1, CBS7435-rESA-PDI-GCN4, CBS7435-rESA-PDI-SEC1, CBS7435-rESA-HAC1-GCN4, CBS7435-rESA-HAC1-SEC1, and CBS7435-rESA-GCN4-SEC1. Pick the positive single colonies of the above strains, inoculate them into 5mL YPD liquid medium for overnight culture, take 1mL and inoculate them into 100mL BMGY medium, culture them at 28℃ and 220rpm until OD600 is about 6, collect the bacteria by centrifugation, transfer to 40mL BMMY medium, and induce them at 25℃ and 220rpm. Add 0.4% methanol every 24h for a total of 72h. After the induction, collect the supernatant for SDS-PAGE detection.
[0226] Experimental Results
[0227] The results are shown in Table 11. Compared with the initial expression strain of recombinant horse albumin (CBS7435-rESA), each molecular chaperone expression strain increased the secretion expression of recombinant horse albumin, among which the expression levels of the co-expressed molecular chaperones PDI-HAC1 and PDI-SEC1 proteins were 1.92 times and 2.03 times higher than the original, respectively.
[0228] Table 11 Expression of recombinant horse albumin in chaperone co-expression strains
[0229] strains Expression ratio CBS7435-rESA 100% CBS7435-rESA-PDI 188% CBS7435-rESA-HAC1 165% CBS7435-rESA-GCN4 173% CBS7435-rESA-SEC1 177% CBS7435-rESA-PDI-HAC1 192% CBS7435-rESA-PDI-GCN4 159% CBS7435-rESA-PDI-SEC1 203% CBS7435-rESA-HAC1-GCN4 151% CBS7435-rESA-HAC1-SEC1 142% CBS7435-rESA-GCN4-SEC1 134%
[0230] The applicant declares that, in the description of the above specification:
[0231] The descriptions of the terms "this embodiment", "an embodiment of the present invention", "as shown in...", "further", "a further improved technical sub-scheme", etc., mean that the specific features, structures, materials or characteristics described in the embodiment or example are included in at least one embodiment or example of the present invention; in this specification, the schematic expressions of the above terms are not necessarily for the same embodiment or example, and the specific features, structures, materials or characteristics described may be combined or combined in a suitable manner in any one or more embodiments or examples; in addition, a person of ordinary skill in the art may combine or combine the different embodiments or examples and the features of the different embodiments or examples described in this specification without causing any contradiction.
[0232] Finally, it should be noted that:
[0233] The above embodiments are only used to illustrate the technical solutions of the present invention, but not to limit them.
[0234] Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some or all of the technical features therein, and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention. The non-essential improvements, adjustments or replacements made by those skilled in the art based on the contents of this specification are all within the scope of protection required by the present invention.
Claims
1. A method for constructing a strain that highly expresses recombinant albumin, characterized in that: The following steps are involved: S1. Construction of albumin initial expression strain; S2, constructing molecular chaperone expression plasmid and combined molecular chaperone expression vector; S3, transforming the molecular chaperone expression plasmid and the combined molecular chaperone expression vector constructed in step S2 into the strain constructed in step S1 respectively, and performing positive screening on the transformed strain; Step S1 includes: S11, optimizing and artificially synthesizing the albumin encoding gene; S12, connecting the optimized sequence to the pPICZαA vector, and the obtained recombinant plasmid was verified to be correct by DNA sequencing; S13, linearizing the plasmid vector by Sac I digestion, and then electrotransforming it into Pichia pastoris CBS7435 competent cells; The optimized albumin coding gene is: Canine albumin encoding gene rCSA, the sequence of which is shown in SEQ ID NO.2; or Feline albumin encoding gene rFSA, the sequence of which is shown in SEQ ID NO.3; or Horse albumin encoding gene rESA, the sequence of which is shown in SEQ ID NO.4; In step S2, the steps of constructing a molecular chaperone expression plasmid include: S21, amplification of the gene sequences of molecular chaperone proteins PDI, HAC1, GCN4, and SEC1; S22, digesting the PCR products of step S21 with Xho I and Not I, and then ligating them to the vector pPIC6 A. The ligation products are named pPIC6 A-PDI, pPIC6 A-HAC1, pPIC6 A-GCN4, and pPIC6 A-SEC1, respectively. The amino acid sequences of the corresponding molecular chaperones are: SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.8, and SEQ ID NO.9, respectively; S23, the recombinant plasmid obtained in step S22 is verified by DNA sequencing; In step S2, the step of constructing a combined molecular chaperone expression vector comprises: using the constructed molecular chaperone plasmid as a backbone, and using the 2A peptide and another molecular chaperone to be inserted as insertion fragments to construct into the downstream of the sequence of the first molecular chaperone, and obtaining the combined molecular chaperone expression vectors, which are named pPIC6 A-PDI-HAC1, pPIC6 A-PDI-GCN4, pPIC6 A-PDI-SEC1, pPIC6 A-HAC1-GCN4, pPIC6 A-HAC1-SEC1, and pPIC6 A-GCN4-SEC1, respectively, and the corresponding molecular chaperone amino acid sequences are: SEQ ID NO.24, SEQ ID NO.25, SEQ ID NO.26, SEQ ID NO.27, SEQ ID NO.28, and SEQ ID NO.29; In step S3, the strains obtained by positive screening are as follows: In the Pichia pastoris CBS7435, the rCSA, the rFSA or the rESA is co-expressed with any of the following combinations: the pPIC6 A-PDI-GCN4, the pPIC6 A-PDI-SEC1, the pPIC6 A-HAC1-GCN4, the pPIC6A-HAC1-SEC1, the pPIC6 A-GCN4-SEC1, the pPIC6 A-GCN4 or the pPIC6 A-SEC1, to obtain the strain highly expressing the recombinant albumin; or In the Pichia pastoris CBS7435, the rCSA or the rESA is co-expressed with any one of the following combinations: the pPIC6 A-PDI, the pPIC6 A-HAC1 or the pPIC6 A-PDI-HAC1, to obtain the strain highly expressing recombinant albumin.
2. A method for constructing a strain that highly expresses recombinant albumin according to claim 1, characterized in that: The P2A nucleotide sequence used is shown in SEQ ID NO.
11.
3. A strain highly expressing recombinant albumin, characterized in that: The strain is constructed by the method according to any one of claims 1-2.
